Contact information
+44 (0)1865 857240
Taryn Hastings
patoruryholman@dtu.ox.ac.uk
Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, OXFORD. OX3 7LJ
Rury Holman
MB, ChB. FRCP(Lon). FMedSci
Emeritus Professor of Diabetic Medicine
- Emeritus Diabetes Trials Unit Director
- Emeritus NIHR Senior Investigator
- Honorary Consultant Physician
Rury Holman trained in medicine at the University of Bristol and was appointed Honorary Consultant Physician to the University of Oxford NHS Hospitals Trust in 1985, at which time he founded the University of Oxford Diabetes Trials Unit. He was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998 and as the founding Academic Chairman of the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) in 2003. He is a Fellow of the Academy of Medical Sciences, an Emeritus NIHR Senior Investigator and Emeritus Professor of Diabetic Medicine. Professor Holman has won many distinguished international awards including the ADA Harold Rifkin Award for Distinguished International Service, the ADA Outstanding Achievement in Clinical Diabetes Research Award, the Diabetes UK Banting Memorial Lecture and the Diabetes UK Robert Turner Award for Research Impact..
Recent publications
-
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.
Journal article
Neves JS. et al, (2024), Eur J Heart Fail
-
Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.
Journal article
Koychev I. et al, (2024), Alzheimers Res Ther, 16
-
Using QALYs as an outcome for assessing global prediction accuracy in diabetes simulation models
Journal article
Dakin H. et al, (2024), Medical Decision Making
-
Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.
Journal article
Oulhaj A. et al, (2024), Diabetes Obes Metab
-
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management.
Journal article
Gao N. et al, (2024), Pharmacoeconomics